The role and prospect of tofacitinib in patients with ulcerative colitis.
作者信息
Lee Jun
机构信息
Department of Internal Medicine, Chosun University College of Medicine, Gwangju, Korea.
出版信息
Intest Res. 2023 Jan;21(1):168-169. doi: 10.5217/ir.2022.00098. Epub 2022 Nov 14.
Abstract
摘要
相似文献
1
The role and prospect of tofacitinib in patients with ulcerative colitis.
Intest Res. 2023 Jan;21(1):168-169. doi: 10.5217/ir.2022.00098. Epub 2022 Nov 14.
2
Tofacitinib Salvage Therapy for Children Hospitalized for Corticosteroid- and Biologic-Refractory Ulcerative Colitis.
J Pediatr Gastroenterol Nutr. 2022 Dec 1;75(6):724-730. doi: 10.1097/MPG.0000000000003616. Epub 2022 Sep 19.
3
Tofacitinib for Rescue Therapy in Acute Severe Ulcerative Colitis: A Real-world Experience.
J Crohns Colitis. 2020 Jul 30;14(7):1026-1028. doi: 10.1093/ecco-jcc/jjaa018.
4
Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
N Engl J Med. 2012 Aug 16;367(7):616-24. doi: 10.1056/NEJMoa1112168.
5
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
N Engl J Med. 2017 May 4;376(18):1723-1736. doi: 10.1056/NEJMoa1606910.
6
Perioperative safety of tofacitinib in surgical ulcerative colitis patients.
Colorectal Dis. 2021 Aug;23(8):2085-2090. doi: 10.1111/codi.15702. Epub 2021 May 24.
7
Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry.
Aliment Pharmacol Ther. 2020 May;51(9):880-888. doi: 10.1111/apt.15689. Epub 2020 Apr 1.
8
Efficacy of tofacitinib treatment in ulcerative colitis.
Gastroenterol Hepatol. 2019 Jun-Jul;42(6):403-412. doi: 10.1016/j.gastrohep.2019.03.002. Epub 2019 May 14.
9
Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program.
Inflamm Bowel Dis. 2023 Jan 5;29(1):27-41. doi: 10.1093/ibd/izac084.
10
Tofacitinib for Biologic-Experienced Hospitalized Patients With Acute Severe Ulcerative Colitis: A Retrospective Case-Control Study.
Clin Gastroenterol Hepatol. 2021 Oct;19(10):2112-2120.e1. doi: 10.1016/j.cgh.2021.05.038. Epub 2021 May 25.
引用本文的文献
1
Safety and effectiveness of tofacitinib in Korean adult patients with ulcerative colitis: post-marketing surveillance study.
BMC Gastroenterol. 2024 Aug 19;24(1):273. doi: 10.1186/s12876-024-03336-2.
本文引用的文献
1
Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis.
Intest Res. 2023 Jan;21(1):61-87. doi: 10.5217/ir.2022.00007. Epub 2022 May 31.
2
Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial.
Intest Res. 2023 Jan;21(1):110-125. doi: 10.5217/ir.2021.00143. Epub 2022 Mar 11.
3
Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study.
Intest Res. 2021 Jan;19(1):71-82. doi: 10.5217/ir.2019.09159. Epub 2020 Sep 4.
4
Long-term outcomes of infliximab in a real-world multicenter cohort of patients with acute severe ulcerative colitis.
Intest Res. 2021 Jul;19(3):323-331. doi: 10.5217/ir.2020.00039. Epub 2020 Aug 18.
5
Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis.
Intest Res. 2021 Jan;19(1):53-61. doi: 10.5217/ir.2019.09146. Epub 2020 Apr 22.
6
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
N Engl J Med. 2019 Sep 26;381(13):1201-1214. doi: 10.1056/NEJMoa1900750.
7
Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis.
Aliment Pharmacol Ther. 2018 Feb;47(4):454-465. doi: 10.1111/apt.14449. Epub 2017 Dec 4.
8
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
N Engl J Med. 2017 May 4;376(18):1723-1736. doi: 10.1056/NEJMoa1606910.
9
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
N Engl J Med. 2013 Aug 22;369(8):699-710. doi: 10.1056/NEJMoa1215734.
10
Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.
Gastroenterology. 2005 Jun;128(7):1805-11. doi: 10.1053/j.gastro.2005.03.003.
Zotero 插件